In MS, HBOT significantly downregulated the expression of ICAM-1 of brain endothelial cells, implicating an inhibition of inflammatory cell migration across the blood brain barrier (BBB) [9]. This evidence concerns the gene ICAM1 and myeloid sarcoma.